- Home
- ORGN vs NKTX Comparison
ORGN vs NKTX Comparison
Compare ORGN & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- NKTX
- Stock Information
- Founded
- ORGN 2008
- NKTX 2015
- Country
- ORGN United States
- NKTX United States
- Employees
- ORGN N/A
- NKTX N/A
- Industry
- ORGN Major Chemicals
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ORGN Industrials
- NKTX Health Care
- Exchange
- ORGN Nasdaq
- NKTX Nasdaq
- Market Cap
- ORGN 199.7M
- NKTX 225.1M
- IPO Year
- ORGN N/A
- NKTX 2020
- Fundamental
- Price
- ORGN $1.01
- NKTX $2.38
- Analyst Decision
- ORGN Strong Buy
- NKTX Strong Buy
- Analyst Count
- ORGN 1
- NKTX 5
- Target Price
- ORGN $3.00
- NKTX $15.20
- AVG Volume (30 Days)
- ORGN 1.2M
- NKTX 2.3M
- Earning Date
- ORGN 11-14-2024
- NKTX 11-07-2024
- Dividend Yield
- ORGN N/A
- NKTX N/A
- EPS Growth
- ORGN N/A
- NKTX N/A
- EPS
- ORGN N/A
- NKTX N/A
- Revenue
- ORGN $35,123,000.00
- NKTX N/A
- Revenue This Year
- ORGN $10.27
- NKTX N/A
- Revenue Next Year
- ORGN $80.25
- NKTX N/A
- P/E Ratio
- ORGN N/A
- NKTX N/A
- Revenue Growth
- ORGN 123.12
- NKTX N/A
- 52 Week Low
- ORGN $0.44
- NKTX $2.08
- 52 Week High
- ORGN $1.90
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- ORGN 30.46
- NKTX 35.48
- Support Level
- ORGN $0.95
- NKTX $2.08
- Resistance Level
- ORGN $1.28
- NKTX $2.39
- Average True Range (ATR)
- ORGN 0.07
- NKTX 0.22
- MACD
- ORGN -0.02
- NKTX 0.00
- Stochastic Oscillator
- ORGN 3.12
- NKTX 16.28
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.